Last reviewed · How we verify
Ferric Hydroxide Polymaltose
Ferric Hydroxide Polymaltose, marketed by South Valley University, is an iron replacement therapy with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and therapeutic efficacy. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Ferric Hydroxide Polymaltose |
|---|---|
| Also known as | haemojet syrp |
| Sponsor | South Valley University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Alternate-day Versus Daily Oral Iron Therapy in Children With Iron Deficiency Anaemia (PHASE4)
- EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY (PHASE1)
- Hypoferritinemia Without Anemia Among Reproductive Age Females (NA)
- Comparison Of Efficacy Of Iron Polymaltose Complex And Ferrous Sulphate In Iron Deficiency Anemia In Pediatric Patients (NA)
- Daily Versus Alternate Day Regimen of Iron Supplementation in Children with Iron Deficiency Anemia (PHASE4)
- Effects of Enhancers and Inhibitors on Absorption From Iron Supplements (NA)
- Evaluation on Performance and Oxydative Stress in Patient With Iron deficIency and Stable Heart Failure Study (PHASE4)
- the Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |